Navigation Links
Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
Date:1/17/2012

HOBOKEN, N.J. and PHILADELPHIA, Jan. 17, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class small molecule that down-regulates GRP78, a key tumor survival and anti-apoptosis factor.

The NKP-1339 single agent dose escalation Phase I trial was conducted in patients with advanced solid tumors resistant to multiple, standard therapies. NKP-1339 was administered intravenously once weekly for 3 weeks followed by one week of no treatment. Thirty-four patients were treated, of which 30 were evaluable for dose determination. The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare in partnership with Translational Genomics Institute, and Dr. Howard Burris, at the Sarah Cannon Research Institute.

The NKP-1339 dose limiting toxicity was grade 2-3 nausea and grade 1-2 reversible renal insufficiency. At the recommended Phase II dose, NKP-1339 treatment was generally well tolerated and had manageable side effects. The most common drug-related side effects were grade 1 nausea, grade 1-2 vomiting and grade 1-2 fatigue. Infusional fever and chills were noted but prevented with steroid premedication.

"We reached our goal to determine the dose of NKP-1339 to take forward in future trials. Many toxicities commonly associated with other anticancer drugs, such as neutropenia, hepatotoxicity, neuropathy, rash, mucositis, diarrhea and alopecia, have not been seen to date," said Dr. Burris.

Anti-tumor activity, demonstrated by disease stability and/or tumor regression for 12-88+ weeks, was noted in patients with neuroendocrine tumors (NET), non-small cell lung cancer, sarcoma, colorectal and cancer of unknown primary. Three patients continue to receive NKP-1339 therapy on study.

"The preliminary read of NKP-1339 anti-tumor activity
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... ALBANY, New York , August 19, 2014 /PRNewswire/ ... " Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... Tappahannock, Va. (PRWEB) August 20, 2014 ... Dr. William Dameron , who joined its Warsaw Medical ... additional physician specialized in Family Medicine, is accepting new ... University School of Medicine, completed his residency at the ... relocating back to Virginia. , “I really like the ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
(Date:8/19/2014)... 2014 Crosley Law Firm, PC has reached ... against Lone Star Bakery for an undisclosed amount. The two ... and May of 2011, respectively. The injuries were caused by ... severe injury to the left hand of each man. , ... Bakery was short-staffed, having lost 200 of its, 500 workers ...
(Date:8/19/2014)... An editorial published in this week,s JAMA ... assessment tools when considering how to treat patients. Written ... Medical Center and chair of pediatrics at Boston University ... JAMA , the editorial examines results of a ... as an example of how doctors can often over-emphasize ...
Breaking Medicine News(10 mins):Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2
... Rating ... , ... (PRWEB) March 23, 2010 -- The Hartville Group Inc., which provides pet health insurance ... Insurance, Hartville Pet Insurance, and the Petshealth Care Plan, has received an A+ rating ...
... ... ... Sir Richard Bowlby keynotes ,Linking Forces, educational event with 16-year history in community , ... , ...
... , March 23 InterMune, Inc. (Nasdaq: ... (MAA), submitted on March 2 seeking approval of ... adults, was validated by the European Medicines Agency (EMA). Validation ... is complete and that the review process will begin on ...
... ... for Haiti survivors. , ... (PRWEB) March 23, 2010 -- Just like any other business, non-profit organizations must ... VoiceNation,s call center agents and auto attendants assist to fill the ...
... ... sustainable solution to the crisis in Haiti. The flexibility of these products can easily make ... ... -- Bosoley Solar Energy’s line of solar lights brings vital illumination to residents and aid ...
... ... than first thought. , ... -- Long known for being an excellent source of fiber, two recent studies suggest that apples ... antioxidants, previous research has suggested that apples may prevent or reduce the risks of certain types ...
Cached Medicine News:Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 2Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 2Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 4Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 2Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 3Health News:Bosoley Solar Light Set to Bring Haiti Out of the Post-Earthquake Darkness 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: